anti-siglec-6 CAR-T cell therapy(Xuzhou Medical University) | Interleukin Related interleukin-related.com

Product Name :
anti-siglec-6 CAR-T cell therapy(Xuzhou Medical University)

Search keywords :
CD33

drugId :
null

Target Vo:
Sialic acid-binding Ig-like lectin 6

Target Vo Short Name :
Siglec-6

Moa_Name:
T lymphocyte replacements

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Xuzhou Medical University (Xzmu)

Active Company_Name :
Xuzhou Medical University (Xzmu)

Active Indication_Name:
Leukemia, Myeloid, Acute

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:
Phase 2 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Vedolizumab Cytoskeleton
Cathepsin K Antibody In Vitro
eIF4E Antibody: eIF4E Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 25 kDa, targeting to eIF4E. It can be used for WB,IHC-P,ICC,FC assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts